Medigene and EpimAb Biotherapeutics have signed a co-development agreement involving T cell receptor (TCR)-guided T cell ...

Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative ...

Scientists at La Trobe University have identified a possible defense for humans against the influenza virus H5N1—commonly ...

A couple facing a terminal multiple myeloma diagnosis finds renewed hope through innovative immunotherapy, transforming blood ...

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...

Wānaka resident and multiple myeloma blood cancer patient Emma Holden, 36, will soon travel to Shanghai, China for ...

Immune cells might be reprogrammed to use the body’s fructose — a naturally occurring sugar — as an energy source that supercharges them to fight cancer, researchers at Memorial Sloan Kettering Cancer ...

Professor Paula Nunes-Hasler, Assistant Professor at the UNIGE Faculty of Medicine, has been awarded INNOGAP and INNOSUISSE grants to advance research on ImmuneCell Booster compounds, a promising new ...

Medigene AG and Epimab Biotherapeutics Inc. have entered a strategic codevelopment agreement to research and develop off-the-shelf T-cell receptor (TCR)-guided T-cell engagers (TCR-TCEs) for the ...

Therapy timing, patient factors, and emerging combination interventions are guiding treatment decisions in multiple myeloma and lymphoma.